참고문헌
- Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res TR 2000;63:213-223 https://doi.org/10.1023/A:1006468514396
- Ministry of Health and Welfare. Annual report of the central cancer registry in Korea, Seoul. Ministry of Health and welfare 2001
- Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast cancer have a poor prognosis than older women. Cancer 1996;77:97-103 https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3
- Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under 35. Cancer 2003;97:134-147 https://doi.org/10.1002/cncr.11051
- Hunter CP. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer 2000;88:1193-1202 https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D
- Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-135
- Choi DH, Shin DB, Lee MH, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587-1595 https://doi.org/10.1002/cncr.11703
- Harris L, Herbert F, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312 https://doi.org/10.1200/JCO.2007.14.2364
- Choi DH, Kim ES, Kim YH, et al. Prognostic significance of COX-2 expression in young Korean patients with invasive breast carcinoma. Suppl. J Clin Oncol 2005;23:829 https://doi.org/10.1200/jco.2005.23.16_suppl.829
- Kennedy SM, Driscoll LO, Purcell R, et al. Prognostic importance of survivin in breast cancer. Brit J Cancer 2003;88:1077-1083 https://doi.org/10.1038/sj.bjc.6600776
- Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-134
- O'Driscoll L, Linehan R, Kennedy S, et al. Lack of prognostic significance of survivin, survivin deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201:225-236 https://doi.org/10.1016/S0304-3835(03)00518-4
- Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chemistry 2004;50:1986-1993 https://doi.org/10.1373/clinchem.2004.039149
- Al-joudi FS, Iskandar ZA, Hasnan J, et al. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Med J 2007;48:607-614
- Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in situ and invasive breast cancer related to COX-2 expression and DCIS recurrence. Br J Cancer 2006;30:253-258
- Son BH, Kwak BS, Kim JK, et al. Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg 2006;141:155-160 https://doi.org/10.1001/archsurg.141.2.155
- Park BW, Kim SI, Kim EK, Yang WI, Lee KS. Impact of patients age on the outcome of primary breast cancer. J Surg Oncol 2002;80:12-18 https://doi.org/10.1002/jso.10088
- Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease free survival in women with operable breast cancer. BMC Cancer 2004;17:82
- Jung MS, Yoon HS, Park EH, Son BH, Ahn SE. Clinical characteristics and prognosis of breast cancer in very young Korean women. Global Breast Conference 2007 Abstract #GBCC01-032
- Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 https://doi.org/10.1038/nm0798-844
- Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256 https://doi.org/10.1016/S0002-9440(10)63075-1
- Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-1717 https://doi.org/10.1016/S0140-6736(05)66544-0
- Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptorpositive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-1291 https://doi.org/10.1200/JCO.1992.10.8.1284
- Choi DH, Kim S, Rimm DL, Carter D, Haffty BG. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J 2005;11:404-411 https://doi.org/10.1097/00130404-200509000-00008
- Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2007;24 (Republication ahead of print)
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182 https://doi.org/10.1126/science.3798106
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med 2005;353:1659-1672 https://doi.org/10.1056/NEJMoa052306
- Choi DH, Lee MH, Ahn YH, et al. Characteristics of HER-2/neu Oncogene in Korean women with early-onset breast cancer by immunohistochemistry and fluorescence in situ hybridization. J Breast Cancer 2003;6:255-262
- Han SW, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a high aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and Cathepsin D protein. J Surg Oncol 1997;65:22-27 https://doi.org/10.1002/(SICI)1096-9098(199705)65:1<22::AID-JSO5>3.0.CO;2-Q
- Park KM, Kim JY, Lim SJ. Comparing fluorescence in situ hybridization and immunohistochemistry to direct HER-2/neu status in breast carcinoma. Korean J Pathol 2002;36:243-248
- Singer-Ranger G, Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer and implications of COX-2 inhibition. Eur J Surg Oncol 2002;28:729-737 https://doi.org/10.1053/ejso.2002.1329
- Half A, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-1681
- Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu positive breast cancer. J Biol Chem 2002;277:18649-18657 https://doi.org/10.1074/jbc.M111415200
- Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635
- Spizzo G, GastlG, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-578 https://doi.org/10.1038/sj.bjc.6600741
- Ahn JH, Kim SB, Ahn SH, et al. Clinical value of cyclooxygenase expression in human breast carcinoma. Cancer Res Treat 2004;36:192-198 https://doi.org/10.4143/crt.2004.36.3.192
- Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative analysis of breast cancer tissue microarrays shows high COX-2 expression is associated with poor outcome. Cancer Invest 2007;25:19-26 https://doi.org/10.1080/07357900601128825
- Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54 https://doi.org/10.1038/nrc968
- Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921 https://doi.org/10.1038/nm0897-917
- Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-4925